6 results on '"Nori, Achyuta V"'
Search Results
2. Mpox in people with past infection or a complete vaccination course: a global case series
- Author
-
Hazra, Aniruddha, primary, Zucker, Jason, additional, Bell, Elizabeth, additional, Flores, John, additional, Gordon, Leanna, additional, Mitjà, Oriol, additional, Suñer, Clara, additional, Lemaignen, Adrien, additional, Jamard, Simon, additional, Nozza, Silvia, additional, Nori, Achyuta V, additional, Pérez-Barragán, Edgar, additional, Rodríguez-Aldama, Juan Carlos, additional, Blanco, Jose Louis, additional, Delaugerre, Constance, additional, Turner, Dan, additional, Fuertes, Irene, additional, Leiro, Viviana, additional, Walmsley, Sharon L, additional, Orkin, Chloe M, additional, Creticos, Catherine, additional, Gibbons, Patrick, additional, Maakaroun-Vermesse, Zoha, additional, Faussat, Cathie, additional, Handala, Lynda, additional, Zeggagh, Jeremy, additional, Alemany, Andrea, additional, Galvan, Cristina, additional, Castagna, Antonella, additional, Raccagni, Angelo Roberto, additional, Cruz-Flores, Raul Adrián, additional, Fernandez Pardal, Patricia, additional, and Marchetta, Lucila, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Self-start HIV postexposure prophylaxis (PEPSE), to reduce time to first dose and increase efficacy.
- Author
-
Fox, Julie M., Ming Jie Lee, Leach Fairhead, Cassandra, Ledwaba-Chapman, Lesedi m., Nori, Achyuta V., McQuillan, Orla, Yanzhong Wang, Clarke, Amanda, and Menon-Johansson, Anatole
- Published
- 2023
- Full Text
- View/download PDF
4. Self-start HIV postexposure prophylaxis (PEPSE), to reduce time to first dose and increase efficacy
- Author
-
Fox, Julie M, primary, Lee, Ming Jie, additional, Fairhead, Cassandra Leach, additional, Ledwaba-Chapman, Lesedi m, additional, Nori, Achyuta V, additional, McQuillan, Orla, additional, Wang, Yanzhong, additional, Clarke, Amanda, additional, and Menon-Johansson, Anatole, additional
- Published
- 2022
- Full Text
- View/download PDF
5. 2016 United Kingdom national guideline on the sexual health care of men who have sex with men
- Author
-
Clutterbuck, Dan, Asboe, David, Barber, Tristan, Emerson, Carol, Field, Nigel, Gibson, Stuart, Hughes, Gwenda, Jones, Rachael, Murchie, Martin, Nori, Achyuta V, Rayment, Michael, and Sullivan, Ann
- Abstract
This guideline is intended for use in UK Genitourinary medicine clinics and sexual health services but is likely to be of relevance in all sexual health settings, including general practice and Contraception and Sexual Health (CASH) services, where men who have sex with men (MSM) seek sexual health care or where addressing the sexual health needs of MSM may have public health benefits. For the purposes of this document, MSM includes all gay, bisexual and all other males who have sex with other males and both cis and trans men. This document does not provide guidance on the treatment of particular conditions where this is covered in other British Association for Sexual Health and HIV (BASHH) Guidelines but outlines best practice in multiple aspects of the sexual health care of MSM. Where prevention of sexually transmitted infections including HIV can be addressed as an integral part of clinical care, this is consistent with the concept of combination prevention and is included. The document is designed primarily to provide guidance on the direct clinical care of MSM but also makes reference to the design and delivery of services with the aim of supporting clinicians and commissioners in providing effective services.Methodology This document was produced in accordance with the guidance set out in the BASHH CEG’s document ‘Framework for guideline development and assessment’ published in 2010 at http://www.bashh.org/guidelinesand with reference to the Agree II instrument. Following the production of the updated framework in April 2015, the GRADE system for assessing evidence was adopted and the draft recommendations were regraded.Search strategy (see also Appendix 1) Ovid Medline 1946 to December 2014, Medline daily update, Embase 1974 to December 2014, Pubmed NeLH Guidelines Database, Cochrane library from 2000 to December 2014. Search language English only. The search for Section 3 was conducted on PubMed to December 2014. Priority was given to peer-reviewed papers published in scientific journals, although for many issues evidence includes conference abstracts listed on the Embase database. In addition, for ‘Identification of problematic recreational drug and alcohol use’ section and ‘Sexual problems and dysfunctions in MSM’ section, searches included PsycINFO.Methods Article titles and abstracts were reviewed and if relevant the full text article was obtained. Priority was given to randomised controlled trial and systematic review evidence, and recommendations made and graded on the basis of best available evidence.Piloting and feedback The first draft of the guideline was circulated to the writing group and to a small group of relevant experts, third sector partners and patient representatives who were invited to comment on the whole document and specifically on particular sections. The revised draft was reviewed by the CEG and then reviewed by the BASHH patient/public panel and posted on the BASHH website for public consultation. The final draft was piloted before publication.Guideline update The guidelines will be reviewed and revised in five years’ time, 2022.
- Published
- 2024
- Full Text
- View/download PDF
6. Mpox in people with past infection or a complete vaccination course: a global case series.
- Author
-
Hazra, Aniruddha, Zucker, Jason, Bell, Elizabeth, Flores, John, Gordon, Leanna, Mitjà, Oriol, Suñer, Clara, Lemaignen, Adrien, Jamard, Simon, Nozza, Silvia, Nori, Achyuta V, Pérez-Barragán, Edgar, Rodríguez-Aldama, Juan Carlos, Blanco, Jose Louis, Delaugerre, Constance, Turner, Dan, Fuertes, Irene, Leiro, Viviana, Walmsley, Sharon L, and Orkin, Chloe M
- Subjects
- *
MONKEYPOX , *SEXUALLY transmitted diseases , *VACCINATION , *BISEXUAL men , *NATURAL immunity - Abstract
Since May, 2022, a large global outbreak of human mpox (formerly known as monkeypox) has predominantly affected men who have sex with men. The strain responsible, Clade IIb, has mutated substantially from precursors originating from the 2017–18 outbreak in Nigeria. Immunity to smallpox, another orthopoxvirus, via previous infection or vaccination provides lifelong immunity. However, since the 2022 mpox outbreak, recent clusters were described in individuals with presumed immunity through recent infection or vaccination. We aim to describe the epidemiological and clinical characteristics of mpox in individuals with past infection or vaccination to improve the understanding of this disease in the setting of previous immunity. In this global case series, international collaborators from nine countries provided data on individuals with PCR-confirmed mpox after documented previous infection or vaccination between May 11, 2022, and June 30, 2023. We excluded cases that could not confirm vaccination status or cases with partial immunisation or any doses received before the current multi-national mpox outbreak (cutoff date May 1, 2022). Data were collected via a case report spreadsheet that reported on dates of infection and vaccination, route of immunisation, demographic characteristics, clinical findings, HIV status, concomitant sexually transmitted infections, and markers of disease severity (mpox severity score system). We describe case epidemiology, clinical course, and mpox severity scores; all analyses were descriptive. We report mpox infections in 37 gay and bisexual men who have sex with men: seven individuals had mpox reinfections, 29 individuals had mpox infections that occurred after two appropriately spaced Modified Vaccinia Ankara-Bavarian Nordic vaccine courses, and one individual had an infection that met the criteria for both reinfection and infection after vaccination. The median age of individuals was 36 years (IQR 30–45; range 21–58). Those with natural immunity after initial infection had a shorter disease course with less mucosal disease upon reinfection than with their initial infection. Infections post-vaccination were characterised by few lesions, little mucosal disease, and minimal analgesia requirements; two people received oral tecovirimat. Overall, there were no deaths, no bacterial superinfections, and all individuals were managed in the ambulatory clinic with one hospital admission for a necrotising neck lesion. The epidemiology of people with mpox reinfection or infection post-vaccination was similar to other published cohorts during the 2022 outbreak—predominantly young, sexually active gay and bisexual men who have sex with men. Clinical features and outcomes of repeat infection and infection after vaccination appear to be less clinically severe than those described in 2022 case literature. Specifically, compared with the 2022 case series, these individuals in the present study had fewer confluent lesions, less mucosal involvement, reduced analgesia requirement, and fewer admissions. Natural immunity and vaccine-induced immunity are not fully protective against mpox infection. However, in this small series both disease duration and severity appear to be reduced. None. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.